B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells

Meng Hsuan Cheng, Yu Chiao Yang, Yun Hong Wong, Tsuei Ru Chen, Chia Yu Lee, Chun Chien Yang, Shih Hua Chen, I. Ning Yang, Ya Shiu Yang, Hsu Shan Huang, Chun Yuh Yang, Ming Shyan Huang, Hui Fen Chiu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In our previous studies, we demonstrated that 2,6-bis-(2-chloroacetamido) anthraquinone (B1) showed a highly significant cytotoxic effect. However, its influence in the cell cycle and apoptotic induction effects has not been investigated yet. Here we report the antiproliferative effect of B1, for which IC 50 values were 0.57 μmol/l for lung cancer A549 cells, 0.63 μmol/l for colon cancer HT-29 cells, and 0.53 μmol/l for breast cancer MCF-7 cells. DNA topoisomerase II (Topo II), an essential enzyme in DNA synthesis and meiotic division, is highly expressed in cancer cells. Some currently used clinical anticancer drugs (doxorubicin and mitoxantrone) targeting Topo II are very effective antineoplastic agents. B1, sharing the basic structure of known Topo II inhibitors, demonstrated a significant inhibitory effect on Topo II bioactivity. In A549 cells, B1 increased apoptotic cell population with induction of Fas, Bax, and cleaved poly(ADP-ribose) polymerase and by reduction of Bcl-2 expression. Moreover, cell cycle analysis indicated that B1 induced G1 phase arrest through modulation of G1 cell cycle regulatory proteins, such as the downregulation of cyclin D1 and upregulation of Cip/p21, Kip1/p27, and p53. Thus, our study suggests that B1, with the ability to inhibit Topo II activity and cause cell cycle G1 arrest and apoptosis, has potential as a novel anticancer agent.

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalAnti-Cancer Drugs
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Fingerprint

Topoisomerase II Inhibitors
G1 Phase Cell Cycle Checkpoints
Type II DNA Topoisomerase
Apoptosis
Antineoplastic Agents
Cell Cycle
Mitoxantrone
HT29 Cells
Cell Cycle Proteins
Poly(ADP-ribose) Polymerases
Cyclin D1
MCF-7 Cells
G1 Phase
Doxorubicin
Colonic Neoplasms
Lung Neoplasms
Up-Regulation
Down-Regulation
Breast Neoplasms
A549 Cells

Keywords

  • anthraquinone
  • apoptosis
  • cell cycle
  • lung cancer
  • topoisomerase II

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Cheng, M. H., Yang, Y. C., Wong, Y. H., Chen, T. R., Lee, C. Y., Yang, C. C., ... Chiu, H. F. (2012). B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells. Anti-Cancer Drugs, 23(2), 191-199. https://doi.org/10.1097/CAD.0b013e32834cd277

B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells. / Cheng, Meng Hsuan; Yang, Yu Chiao; Wong, Yun Hong; Chen, Tsuei Ru; Lee, Chia Yu; Yang, Chun Chien; Chen, Shih Hua; Yang, I. Ning; Yang, Ya Shiu; Huang, Hsu Shan; Yang, Chun Yuh; Huang, Ming Shyan; Chiu, Hui Fen.

In: Anti-Cancer Drugs, Vol. 23, No. 2, 02.2012, p. 191-199.

Research output: Contribution to journalArticle

Cheng, MH, Yang, YC, Wong, YH, Chen, TR, Lee, CY, Yang, CC, Chen, SH, Yang, IN, Yang, YS, Huang, HS, Yang, CY, Huang, MS & Chiu, HF 2012, 'B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells', Anti-Cancer Drugs, vol. 23, no. 2, pp. 191-199. https://doi.org/10.1097/CAD.0b013e32834cd277
Cheng, Meng Hsuan ; Yang, Yu Chiao ; Wong, Yun Hong ; Chen, Tsuei Ru ; Lee, Chia Yu ; Yang, Chun Chien ; Chen, Shih Hua ; Yang, I. Ning ; Yang, Ya Shiu ; Huang, Hsu Shan ; Yang, Chun Yuh ; Huang, Ming Shyan ; Chiu, Hui Fen. / B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells. In: Anti-Cancer Drugs. 2012 ; Vol. 23, No. 2. pp. 191-199.
@article{1cfb6bb08d974d61bb01407d98d2a916,
title = "B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells",
abstract = "In our previous studies, we demonstrated that 2,6-bis-(2-chloroacetamido) anthraquinone (B1) showed a highly significant cytotoxic effect. However, its influence in the cell cycle and apoptotic induction effects has not been investigated yet. Here we report the antiproliferative effect of B1, for which IC 50 values were 0.57 μmol/l for lung cancer A549 cells, 0.63 μmol/l for colon cancer HT-29 cells, and 0.53 μmol/l for breast cancer MCF-7 cells. DNA topoisomerase II (Topo II), an essential enzyme in DNA synthesis and meiotic division, is highly expressed in cancer cells. Some currently used clinical anticancer drugs (doxorubicin and mitoxantrone) targeting Topo II are very effective antineoplastic agents. B1, sharing the basic structure of known Topo II inhibitors, demonstrated a significant inhibitory effect on Topo II bioactivity. In A549 cells, B1 increased apoptotic cell population with induction of Fas, Bax, and cleaved poly(ADP-ribose) polymerase and by reduction of Bcl-2 expression. Moreover, cell cycle analysis indicated that B1 induced G1 phase arrest through modulation of G1 cell cycle regulatory proteins, such as the downregulation of cyclin D1 and upregulation of Cip/p21, Kip1/p27, and p53. Thus, our study suggests that B1, with the ability to inhibit Topo II activity and cause cell cycle G1 arrest and apoptosis, has potential as a novel anticancer agent.",
keywords = "anthraquinone, apoptosis, cell cycle, lung cancer, topoisomerase II",
author = "Cheng, {Meng Hsuan} and Yang, {Yu Chiao} and Wong, {Yun Hong} and Chen, {Tsuei Ru} and Lee, {Chia Yu} and Yang, {Chun Chien} and Chen, {Shih Hua} and Yang, {I. Ning} and Yang, {Ya Shiu} and Huang, {Hsu Shan} and Yang, {Chun Yuh} and Huang, {Ming Shyan} and Chiu, {Hui Fen}",
year = "2012",
month = "2",
doi = "10.1097/CAD.0b013e32834cd277",
language = "English",
volume = "23",
pages = "191--199",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells

AU - Cheng, Meng Hsuan

AU - Yang, Yu Chiao

AU - Wong, Yun Hong

AU - Chen, Tsuei Ru

AU - Lee, Chia Yu

AU - Yang, Chun Chien

AU - Chen, Shih Hua

AU - Yang, I. Ning

AU - Yang, Ya Shiu

AU - Huang, Hsu Shan

AU - Yang, Chun Yuh

AU - Huang, Ming Shyan

AU - Chiu, Hui Fen

PY - 2012/2

Y1 - 2012/2

N2 - In our previous studies, we demonstrated that 2,6-bis-(2-chloroacetamido) anthraquinone (B1) showed a highly significant cytotoxic effect. However, its influence in the cell cycle and apoptotic induction effects has not been investigated yet. Here we report the antiproliferative effect of B1, for which IC 50 values were 0.57 μmol/l for lung cancer A549 cells, 0.63 μmol/l for colon cancer HT-29 cells, and 0.53 μmol/l for breast cancer MCF-7 cells. DNA topoisomerase II (Topo II), an essential enzyme in DNA synthesis and meiotic division, is highly expressed in cancer cells. Some currently used clinical anticancer drugs (doxorubicin and mitoxantrone) targeting Topo II are very effective antineoplastic agents. B1, sharing the basic structure of known Topo II inhibitors, demonstrated a significant inhibitory effect on Topo II bioactivity. In A549 cells, B1 increased apoptotic cell population with induction of Fas, Bax, and cleaved poly(ADP-ribose) polymerase and by reduction of Bcl-2 expression. Moreover, cell cycle analysis indicated that B1 induced G1 phase arrest through modulation of G1 cell cycle regulatory proteins, such as the downregulation of cyclin D1 and upregulation of Cip/p21, Kip1/p27, and p53. Thus, our study suggests that B1, with the ability to inhibit Topo II activity and cause cell cycle G1 arrest and apoptosis, has potential as a novel anticancer agent.

AB - In our previous studies, we demonstrated that 2,6-bis-(2-chloroacetamido) anthraquinone (B1) showed a highly significant cytotoxic effect. However, its influence in the cell cycle and apoptotic induction effects has not been investigated yet. Here we report the antiproliferative effect of B1, for which IC 50 values were 0.57 μmol/l for lung cancer A549 cells, 0.63 μmol/l for colon cancer HT-29 cells, and 0.53 μmol/l for breast cancer MCF-7 cells. DNA topoisomerase II (Topo II), an essential enzyme in DNA synthesis and meiotic division, is highly expressed in cancer cells. Some currently used clinical anticancer drugs (doxorubicin and mitoxantrone) targeting Topo II are very effective antineoplastic agents. B1, sharing the basic structure of known Topo II inhibitors, demonstrated a significant inhibitory effect on Topo II bioactivity. In A549 cells, B1 increased apoptotic cell population with induction of Fas, Bax, and cleaved poly(ADP-ribose) polymerase and by reduction of Bcl-2 expression. Moreover, cell cycle analysis indicated that B1 induced G1 phase arrest through modulation of G1 cell cycle regulatory proteins, such as the downregulation of cyclin D1 and upregulation of Cip/p21, Kip1/p27, and p53. Thus, our study suggests that B1, with the ability to inhibit Topo II activity and cause cell cycle G1 arrest and apoptosis, has potential as a novel anticancer agent.

KW - anthraquinone

KW - apoptosis

KW - cell cycle

KW - lung cancer

KW - topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=84855253165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855253165&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32834cd277

DO - 10.1097/CAD.0b013e32834cd277

M3 - Article

C2 - 22008852

AN - SCOPUS:84855253165

VL - 23

SP - 191

EP - 199

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -